Literature DB >> 19428830

The novel adjuvant combination of CpG ODN, indolicidin and polyphosphazene induces potent antibody- and cell-mediated immune responses in mice.

J Kovacs-Nolan1, L Latimer, A Landi, H Jenssen, R E W Hancock, L A Babiuk, S van Drunen Littel-van den Hurk.   

Abstract

The need to enhance the immunogenicity of purified subunit antigens and modulate resulting immune responses has prompted the development of new adjuvants. Here, the ability of CpG oligodeoxynucleotides (ODN), a bovine host defence peptide indolicidin, and polyphosphazene to synergistically combine and enhance innate and adaptive immune responses was examined in mice. In vitro, the adjuvant combination of CpG ODN, indolicidin and polyphosphazene (CpG/indol/PP) enhanced the secretion of TNF-alpha, IL-12p40, and IL-6 by bone marrow-derived DCs (BMDCs) when compared to the individual components. When co-formulated with ovalbumin (OVA), CpG/indol/PP formed antigen-adjuvant complexes, and enhanced antibody and cell-mediated responses in mice, via both MHC I and II pathways, promoting a more balanced antibody-mediated and type 1-biased cell-mediated immune response. Furthermore, substitution of the proline residues of indolicidin with arginine increased the synergistic adjuvant effect of the peptide, and induced significantly higher IgG1 and IgG2a titers and IFN-gamma secretion, as well as increased uptake by antigen presenting cells. These results clearly demonstrate that the use of a combination of CpG ODN, indolicidin, and polyphosphazene as adjuvant can significantly enhance an antigen-specific immune response.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19428830     DOI: 10.1016/j.vaccine.2009.01.118

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  18 in total

1.  Incorporation of the TLR4 agonist monophosphoryl lipid A into the bilayer of DDA/TDB liposomes: physico-chemical characterization and induction of CD8+ T-cell responses in vivo.

Authors:  Pernille Nordly; Else Marie Agger; Peter Andersen; Hanne Mørck Nielsen; Camilla Foged
Journal:  Pharm Res       Date:  2010-11-02       Impact factor: 4.200

2.  Enzymatic stability and immunoregulatory efficacy of a synthetic indolicidin analogue with regular enantiomeric sequence.

Authors:  Ching-Yun Chang; Chih-Wei Lin; Sheng-Kuo Chiang; Po-Ling Chen; Chiung-Yi Huang; Shih-Jen Liu; Pele Chong; Ming-Hsi Huang
Journal:  ACS Med Chem Lett       Date:  2013-04-24       Impact factor: 4.345

3.  In vitro analysis of acetalated dextran microparticles as a potent delivery platform for vaccine adjuvants.

Authors:  Eric M Bachelder; Tristan T Beaudette; Kyle E Broaders; Jean M J Fréchet; Mark T Albrecht; Alfred J Mateczun; Kristy M Ainslie; John T Pesce; Andrea M Keane-Myers
Journal:  Mol Pharm       Date:  2010-06-07       Impact factor: 4.939

4.  Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice.

Authors:  Ming-Hsi Huang; Su-Chen Lin; Chia-Hsin Hsiao; Hsin-Ju Chao; Hung-Ren Yang; Chien-Chun Liao; Po-Wei Chuang; Huang-Pi Wu; Chiung-Yi Huang; Chih-Hsiang Leng; Shih-Jen Liu; Hsin-Wei Chen; Ai-Hsiang Chou; Alan Yung-Chih Hu; Pele Chong
Journal:  PLoS One       Date:  2010-08-19       Impact factor: 3.240

Review 5.  Polyphosphazene immunoadjuvants: Historical perspective and recent advances.

Authors:  Alexander K Andrianov; Robert Langer
Journal:  J Control Release       Date:  2020-12-05       Impact factor: 9.776

6.  Therapeutic approaches using host defence peptides to tackle herpes virus infections.

Authors:  Håvard Jenssen
Journal:  Viruses       Date:  2009-11-18       Impact factor: 5.048

7.  Low dose antigen exposure for a finite period in newborn rats prevents induction of mucosal tolerance.

Authors:  Rachelle M Buchanan; Sherry Tetland; Heather L Wilson
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

8.  Oral antigen exposure in extreme early life in lambs influences the magnitude of the immune response which can be generated in later life.

Authors:  Rachelle M Buchanan; Sonja Mertins; Heather L Wilson
Journal:  BMC Vet Res       Date:  2013-08-12       Impact factor: 2.741

9.  Caspase-1 Dependent IL-1β Secretion and Antigen-Specific T-Cell Activation by the Novel Adjuvant, PCEP.

Authors:  Sunita Awate; Nelson F Eng; Volker Gerdts; Lorne A Babiuk; George Mutwiri
Journal:  Vaccines (Basel)       Date:  2014-06-26

10.  In Vivo and In Vitro Potency of Polyphosphazene Immunoadjuvants with Hepatitis C Virus Antigen and the Role of Their Supramolecular Assembly.

Authors:  Alexander K Andrianov; Alexander Marin; Ruixue Wang; Ananda Chowdhury; Pragati Agnihotri; Abdul S Yunus; Brian G Pierce; Roy A Mariuzza; Thomas R Fuerst
Journal:  Mol Pharm       Date:  2020-06-23       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.